Company news

Kymera Therapeutics, Inc. news in 2025

Kymera Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 10, 2025

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

December 10, 2025

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

December 8, 2025

Kymera Therapeutics Announces Proposed Public Offering

December 7, 2025

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

December 7, 2025

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

December 4, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

November 24, 2025

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

November 23, 2025

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

November 3, 2025

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

November 2, 2025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

October 27, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

October 26, 2025

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

September 16, 2025

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

September 2, 2025

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

August 26, 2025

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

August 10, 2025

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

August 3, 2025

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

June 25, 2025

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

June 24, 2025

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

June 24, 2025

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

June 1, 2025

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

May 29, 2025

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

May 18, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

May 8, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

May 8, 2025

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

May 6, 2025

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

April 23, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

April 21, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

April 8, 2025

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

February 26, 2025

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

February 25, 2025

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

February 19, 2025

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

January 13, 2025

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

January 6, 2025

Calls in 2025

Decks in 2025